Table 3 The description of PTM-loaded nanocarriers against cancer
Formulation | Preparation technique | Cancer type | Subject | Advantage | Reference |
|---|---|---|---|---|---|
Squalene-based nanoparticles of PTM | Nanoprecipitation | Breast, prostate, and liver cancer | MCF7, MDA-MB-231, LNCap, PC-3, and HepG2 cells | A superior cytotoxicity compared to free PTM-B and preferential accumulation in cells overexpressing the LDL receptor | [38] |
PTM-hyaluronic acid polyelectrolyte complexes | Polyelectrolyte complexation | Lung and breast cancer | A549 and MDA-MB-231 cells | More cytotoxicity in comparison to the free drug and enhanced internalization of encapsulated drugs by cancer cells | [41] |
Pegylated liposomal PTM | Thin film hydration | Colorectal, ovarian, lung, and breast cancer | Female SCID mice bearing subcutaneous HT29, A549, SKOV3, or orthotopic MDA-MB-231 tumors | Improved biodistribution and tumor accumulation, as well as decreased kidney drug levels compared to the free drug | [35] |
Chitosan coated niosome of PTM | Thin film hydration | Colon cancer | Human biopsies of colon cancer | Maximized drug permeabilization in the tissue | [45] |
PTM-loaded poly(lactide-co-glycolide) nanoparticles & Liposomal PTM | Nanoprecipitation & Thin film hydration | Ovarian cancer | A2780 cells | Higher cytotoxicity of PLGA nanoparticles compared to liposomes | [36] |
PTM-loaded PLGA/HA-DPPE nanoparticles | Nanoprecipitation | Breast cancer | MCF-7 and MDA-MB-231 cells | Higher cytotoxicity of PTM-B-loaded PLGA/HA-DPPE nanoparticles compared to the free PTM-B and PTM-B-loaded PLGA nanoparticles in the CD44-expressing cells | [129] |